Anna Holgado , Xavier León , Miquel Quer , Valle Camacho , Alejando Fernández
{"title":"放射治疗口咽癌患者最大标准化摄取值与局部控制的关系","authors":"Anna Holgado , Xavier León , Miquel Quer , Valle Camacho , Alejando Fernández","doi":"10.1016/j.otorri.2022.05.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To analyse the prognostic ability of the maximum standardised uptake value (SUV<sub>max</sub>) on local disease control in patients with oropharyngeal carcinoma treated with radiotherapy.</p></div><div><h3>Material and methods</h3><p>Retrospective study of 105 patients with oropharyngeal carcinomas treated with radiotherapy, including chemo- and bio-radiotherapy, and who had a PET-CT scan prior to the start of treatment.</p></div><div><h3>Result</h3><p>Patients with a SUV<sub>max</sub> value higher than 17.2 at the primary tumour site had a significantly higher risk of local recurrence. The 5-year local recurrence-free survival for patients with SUV<sub>max</sub> less than or equal to 17.2 (<em>n</em> <!-->=<!--> <!-->71) was 86.5% (95% CI: 78.2–94.7%), and for patients with SUV<sub>max</sub> greater than 17.2 (<em>n</em> <!-->=<!--> <!-->34) it was 55.8% (95% CI: 36.0–75.6%) (<em>P</em>=.0001). This difference in local control was maintained regardless of patients’ HPV status. Specific survival was similarly lower for patients with a SUV greater than 17.2. The 5-year specific survival for patients with SUV<sub>max</sub> greater than 17.2 was 39.5% (95% CI: 20.6–58.3%), significantly shorter than that of patients with SUV<sub>max</sub> equal to or less than 17.2, which was 77.3% (95% CI: 66.9–87.6%) (<em>P</em>=.0001).</p></div><div><h3>Conclusions</h3><p>Patients with oropharyngeal carcinomas treated with radiotherapy with a SUV<sub>max</sub> greater than 17.2 at the level of the primary tumour site had a significantly higher risk of local recurrence.</p></div>","PeriodicalId":7019,"journal":{"name":"Acta otorrinolaringologica espanola","volume":"74 4","pages":"Pages 211-218"},"PeriodicalIF":0.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Asociación entre el standarized uptake value (SUV) máximo y el control local en pacientes con carcinoma de orofaringe tratados con radioterapia\",\"authors\":\"Anna Holgado , Xavier León , Miquel Quer , Valle Camacho , Alejando Fernández\",\"doi\":\"10.1016/j.otorri.2022.05.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To analyse the prognostic ability of the maximum standardised uptake value (SUV<sub>max</sub>) on local disease control in patients with oropharyngeal carcinoma treated with radiotherapy.</p></div><div><h3>Material and methods</h3><p>Retrospective study of 105 patients with oropharyngeal carcinomas treated with radiotherapy, including chemo- and bio-radiotherapy, and who had a PET-CT scan prior to the start of treatment.</p></div><div><h3>Result</h3><p>Patients with a SUV<sub>max</sub> value higher than 17.2 at the primary tumour site had a significantly higher risk of local recurrence. The 5-year local recurrence-free survival for patients with SUV<sub>max</sub> less than or equal to 17.2 (<em>n</em> <!-->=<!--> <!-->71) was 86.5% (95% CI: 78.2–94.7%), and for patients with SUV<sub>max</sub> greater than 17.2 (<em>n</em> <!-->=<!--> <!-->34) it was 55.8% (95% CI: 36.0–75.6%) (<em>P</em>=.0001). This difference in local control was maintained regardless of patients’ HPV status. Specific survival was similarly lower for patients with a SUV greater than 17.2. The 5-year specific survival for patients with SUV<sub>max</sub> greater than 17.2 was 39.5% (95% CI: 20.6–58.3%), significantly shorter than that of patients with SUV<sub>max</sub> equal to or less than 17.2, which was 77.3% (95% CI: 66.9–87.6%) (<em>P</em>=.0001).</p></div><div><h3>Conclusions</h3><p>Patients with oropharyngeal carcinomas treated with radiotherapy with a SUV<sub>max</sub> greater than 17.2 at the level of the primary tumour site had a significantly higher risk of local recurrence.</p></div>\",\"PeriodicalId\":7019,\"journal\":{\"name\":\"Acta otorrinolaringologica espanola\",\"volume\":\"74 4\",\"pages\":\"Pages 211-218\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta otorrinolaringologica espanola\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0001651922000863\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta otorrinolaringologica espanola","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001651922000863","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
Asociación entre el standarized uptake value (SUV) máximo y el control local en pacientes con carcinoma de orofaringe tratados con radioterapia
Objective
To analyse the prognostic ability of the maximum standardised uptake value (SUVmax) on local disease control in patients with oropharyngeal carcinoma treated with radiotherapy.
Material and methods
Retrospective study of 105 patients with oropharyngeal carcinomas treated with radiotherapy, including chemo- and bio-radiotherapy, and who had a PET-CT scan prior to the start of treatment.
Result
Patients with a SUVmax value higher than 17.2 at the primary tumour site had a significantly higher risk of local recurrence. The 5-year local recurrence-free survival for patients with SUVmax less than or equal to 17.2 (n = 71) was 86.5% (95% CI: 78.2–94.7%), and for patients with SUVmax greater than 17.2 (n = 34) it was 55.8% (95% CI: 36.0–75.6%) (P=.0001). This difference in local control was maintained regardless of patients’ HPV status. Specific survival was similarly lower for patients with a SUV greater than 17.2. The 5-year specific survival for patients with SUVmax greater than 17.2 was 39.5% (95% CI: 20.6–58.3%), significantly shorter than that of patients with SUVmax equal to or less than 17.2, which was 77.3% (95% CI: 66.9–87.6%) (P=.0001).
Conclusions
Patients with oropharyngeal carcinomas treated with radiotherapy with a SUVmax greater than 17.2 at the level of the primary tumour site had a significantly higher risk of local recurrence.
期刊介绍:
Es la revista más importante en español dedicada a la especialidad. Ofrece progresos científicos y técnicos tanto a nivel de originales como de casos clínicos. Además, es la Publicación Oficial de la Sociedad Española de Otorrinolaringología y Patología Cérvico-Facial y está presente en los más prestigiosos índices de referencia.